Nanjing Fusheng Pharmaceutical

Nanjing Fusheng Pharmaceutical Technology Co., Ltd. is a biopharmaceutical company based in Nanjing, China, specializing in the development of innovative therapies for oncology and infectious diseases. The company's research and development efforts span both small molecule drugs and traditional Chinese medicine (TCM). Its lead pipeline candidate, Longqi Capsule, is a TCM currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC). Nanjing Fusheng also markets anti-infective products, such as Cefotaxime Sodium/Tazobactam Sodium, which is used to treat various bacterial infections. The company maintains a close strategic relationship with Nanjing Yoko Pharmaceutical, a major player in the Chinese pharmaceutical sector.